ZNTL
Zentalis Pharmaceuticals (ZNTL) P/E Ratio
P/E Ratio as of Oct 29, 2026: -1.02
Average-1.22
Median-1.23
Minimum-1.42
Maximum-1.01
-1.02
0.37 (26.62%)past month
The P/E ratio for Zentalis Pharmaceuticals (ZNTL) is -1.02 as of Oct 29, 2026. This represents a decrease of -34.19% compared to its 12-month average P/E ratio of -1.55. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Zentalis Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Zentalis Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Zentalis Pharmaceuticals to industry peers.
Zentalis Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Zentalis Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Zentalis Pharmaceuticals to industry peers.
Zentalis Pharmaceuticals (ZNTL) P/E Ratio Insights
See Zentalis Pharmaceuticals’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Zentalis Pharmaceuticals (ZNTL)
Order type
Buy in
Order amount
Est. shares
0 shares
Zentalis Pharmaceuticals (ZNTL) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Oct 1, 2026 | $2.605 | -1.33 |
| Sep 1, 2026 | $3.71 | -1.90 |
| Aug 3, 2026 | $4.65 | -2.68 |
| Jul 1, 2026 | $4.355 | -2.51 |
| Jun 1, 2026 | $3.98 | -2.29 |
| May 1, 2026 | $4.09 | -2.14 |
| Apr 1, 2026 | $2.57 | -1.35 |
| Mar 2, 2026 | $2.50 | -1.20 |
| Feb 2, 2026 | $2.51 | -1.20 |
| Jan 2, 2026 | $1.37 | -0.66 |
Zentalis Pharmaceuticals (ZNTL) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2026 | -1.02 | +56.92% |
| 2025 | -0.65 | -45.83% |
| 2024 | -1.20 | -63.30% |
| 2023 | -3.27 | -23.42% |
| 2022 | -4.27 | -80.78% |
| 2021 | -22.22 | — |
FAQs About Zentalis Pharmaceuticals (ZNTL) P/E ratio
The latest P/E ratio of Zentalis Pharmaceuticals (ZNTL) is -1.02, as of Oct 29, 2026. This is calculated based on its current stock price and earnings per share (EPS).
Zentalis Pharmaceuticals’s last 12-month average P/E ratio is -1.55, compared to its current P/E ratio of -1.02. This reflects a decrease of -34.19%.
Zentalis Pharmaceuticals’s current P/E ratio of -1.02 is lower than its last 12-month average P/E of -1.55. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Zentalis Pharmaceuticals’s average P/E ratio over the last 3 years is -1.67. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Zentalis Pharmaceuticals’s average P/E ratio over the last 5 years is -4.42. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.
Zentalis Pharmaceuticals (ZNTL) P/E Ratio Insights
See Zentalis Pharmaceuticals’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Zentalis Pharmaceuticals (ZNTL)
Order type
Buy in
Order amount
Est. shares
0 shares
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.